

August 8, 2024



## Ocuphire Pharma to Present at Two Investor Conferences in August

FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that George Magrath, M.D., M.B.A., M.S., Chief Executive Officer, will present at the [Canaccord Genuity 44<sup>th</sup> Annual Growth Conference](#), to take place in Boston, MA, August 14, 2024, and at the [H.C. Wainwright 4<sup>th</sup> Annual Ophthalmology Virtual Conference](#), to take place virtually, on August 15, 2024.

**Event:** Canaccord Genuity 44<sup>th</sup> Annual Growth Conference  
**Location:** Boston, MA  
**Presenter:** Dr. George Magrath  
**Date:** August 14, 2024  
**Time:** 9:00 a.m. ET  
**Format:** Fireside Chat

**Event:** H.C. Wainwright 4<sup>th</sup> Annual Ophthalmology Virtual Conference  
**Location:** Virtual  
**Presenter:** Dr. George Magrath  
**Date:** August 15, 2024  
**Time:** 10:30 a.m. ET  
**Format:** Presentation

Company management will also be available for one-on-one meetings throughout the conferences. If you are interested in arranging a meeting, please contact your conference representative or send an email to [ir@ocuphire.com](mailto:ir@ocuphire.com).

### About Ocuphire Pharma

Ocuphire Pharma, Inc. (Nasdaq: OCUP) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of patients with retinal and refractive eye disorders. Ocuphire's lead product candidate, APX3330, a novel small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein), is in development for diabetic retinopathy. In addition, Ocuphire's late-stage product candidate Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, is being developed for presbyopia and

dim (mesopic) light vision disturbances and is currently approved and marketed by our partner as RYZUMVI™ for reversal of pharmacologically induced mydriasis. For more information, please visit [www.ocuphire.com](http://www.ocuphire.com).

## Contacts

Corporate	Investor Relations
Nirav Jhaveri, M.B.A. CFO <a href="mailto:ir@ocuphire.com">ir@ocuphire.com</a>	Corey Davis, Ph.D. LifeSci Advisors <a href="mailto:cdavis@lifesciadvisors.com">cdavis@lifesciadvisors.com</a>



Source: Ocuphire Pharma